Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
 
NCT02735707
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 mild to moderatesome concern
1190/1054 conclusif
  • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
atypical endpoints without correspondence with those of the others trials
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
 
NCT02735707
RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
1190/1054 conclusif
  • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
atypical endpoints without correspondence with those of the others trials

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).